Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Alumis, Priovant Therapeutics, Takeda, Galapagos, Oncostellae, Neuron23, Haisco Pharmaceutical, Sareum, Oncostella

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tyrosine Kinase 2 (TYK2) Inhibitors pipeline constitutes 15+ key companies continuously working towards developing 15+ Tyrosine Kinase 2 (TYK2) Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tyrosine Kinase 2 (TYK2) Inhibitors Market.

Some of the key takeaways from the Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Report: https://www.delveinsight.com/sample-request/tyk2-kinase-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Tyrosine Kinase 2 (TYK2) Inhibitors treatment therapies with a considerable amount of success over the years.
• Tyrosine Kinase 2 (TYK2) Inhibitors companies working in the treatment market are Alumis, Priovant Therapeutics, Takeda, Galapagos, Oncostellae, Neuron23, Sudo Biosciences, Sareum Holdings PLC, Ventyx Biosciences, Nimbus Therapeutics, Bristol-Myers Squibb, Priovant Therapeutics, and others, are developing therapies for the Tyrosine Kinase 2 (TYK2) Inhibitors treatment
• Emerging Tyrosine Kinase 2 (TYK2) Inhibitors therapies in the different phases of clinical trials are- ESK-001, Brepocitinib, Zasocitinib, GLPG3667, OST-122, NEU-111, TYK2 Inhibitors, SDC-1801, GLPG3667, VTX958, NDI-034858, Sotyktu, Brepocitinib, and others are expected to have a significant impact on the Tyrosine Kinase 2 (TYK2) Inhibitors market in the coming years.
• In March 2025, Alumis reported favorable 52-week results from the open-label extension of its Phase II STRIDE trial assessing ESK-001 in patients with moderate-to-severe plaque psoriasis. These findings were shared during a late-breaking session at the 2025 American Academy of Dermatology Association (AAD) Annual Meeting.
• In December 2024, Neuron23® Inc., a clinical-stage biotechnology firm focused on developing precision therapies for genetically driven neurological and immunological conditions, has announced the initiation of dosing in its Phase 1 clinical trial of NEU-111 in healthy participants. NEU-111 is a potent and highly selective oral allosteric inhibitor of tyrosine kinase 2 (TYK2), a member of the JAK protein family that plays a key role in abnormal immune signaling.
• In December 2024, Bristol Myers Squibb (NYSE: BMY) has shared findings from the Phase 3 POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055) trials, which evaluated the safety and effectiveness of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both studies achieved their primary goal, with a significantly greater number of patients receiving Sotyktu reaching an ACR20 response-indicating at least a 20% improvement in disease symptoms-after 16 weeks, compared to those on placebo. These outcomes underscore Sotyktu's potential as the first TYK2 inhibitor for PsA and support its consistent safety and efficacy profile.
• In March 2024, Alumis Inc., a clinical-stage biopharmaceutical company focused on developing oral treatments for immune-mediated diseases, has reported positive results from a Phase 2 clinical trial of ESK-001. This novel therapy is a precisely targeted allosteric inhibitor of tyrosine kinase 2 (TYK2) and has demonstrated potential in managing moderate-to-severe plaque psoriasis.

Tyrosine Kinase 2 (TYK2) Inhibitors Overview
Tyrosine kinase 2 (TYK2) inhibitors are a class of pharmaceutical compounds designed to inhibit the activity of the TYK2 enzyme. TYK2 is a member of the Janus kinase (JAK) family of enzymes, which play a crucial role in signal transduction pathways involved in immune responses and inflammation. In particular, TYK2 is involved in the signaling of cytokines, which are proteins that regulate various immune and inflammatory processes.

Get a Free Sample PDF Report to know more about Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/tyk2-kinase-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Tyrosine Kinase 2 (TYK2) Inhibitors Drugs Under Different Phases of Clinical Development Include:
• ESK-001: Alumis
• Brepocitinib: Priovant Therapeutics
• Zasocitinib: Takeda
• GLPG3667: Galapagos
• OST-122: Oncostellae
• NEU-111: Neuron23
• TYK2 Inhibitors: Sudo Biosciences
• SDC-1801: Sareum Holdings PLC
• GLPG3667: Galapagos NV
• VTX958: Ventyx Biosciences
• NDI-034858: Nimbus Therapeutics
• Sotyktu: Bristol-Myers Squibb
• Brepocitinib: Priovant Therapeutics

Tyrosine Kinase 2 (TYK2) Inhibitors Route of Administration
Tyrosine Kinase 2 (TYK2) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Tyrosine Kinase 2 (TYK2) Inhibitors Molecule Type
Tyrosine Kinase 2 (TYK2) Inhibitors Products have been categorized under various Molecule types, such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Therapeutics Assessment
• Tyrosine Kinase 2 (TYK2) Inhibitors Assessment by Product Type
• Tyrosine Kinase 2 (TYK2) Inhibitors By Stage and Product Type
• Tyrosine Kinase 2 (TYK2) Inhibitors Assessment by Route of Administration
• Tyrosine Kinase 2 (TYK2) Inhibitors By Stage and Route of Administration
• Tyrosine Kinase 2 (TYK2) Inhibitors Assessment by Molecule Type
• Tyrosine Kinase 2 (TYK2) Inhibitors by Stage and Molecule Type

DelveInsight's Tyrosine Kinase 2 (TYK2) Inhibitors Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Tyrosine Kinase 2 (TYK2) Inhibitors product details are provided in the report. Download the Tyrosine Kinase 2 (TYK2) Inhibitors pipeline report to learn more about the emerging Tyrosine Kinase 2 (TYK2) Inhibitors therapies
https://www.delveinsight.com/sample-request/tyk2-kinase-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Tyrosine Kinase 2 (TYK2) Inhibitors Therapeutics Market include:
Key companies developing therapies for Tyrosine Kinase 2 (TYK2) Inhibitors are - Galapagos, Haisco Pharmaceutical Group, Sareum, Oncostellae, Incyte Corporation, Bristol-Myers Squibb, Oncostellae, Pfizer, and others.

Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Analysis:
The Tyrosine Kinase 2 (TYK2) Inhibitors pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Tyrosine Kinase 2 (TYK2) Inhibitors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tyrosine Kinase 2 (TYK2) Inhibitors Treatment.
• Tyrosine Kinase 2 (TYK2) Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Tyrosine Kinase 2 (TYK2) Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Tyrosine Kinase 2 (TYK2) Inhibitors market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Tyrosine Kinase 2 (TYK2) Inhibitors drugs and therapies
https://www.delveinsight.com/sample-request/tyk2-kinase-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Market Drivers
• Rise in the global prevalence of autoimmune disorders, huge investment in the R&D activities, technological advancements and innovations are some of the important factors that are fueling the Tyrosine Kinase 2 (TYK2) Inhibitors Market.

Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Market Barriers
• However, adverse reactions induced by TYK2 inhibitors such as gastrointestinal infections, high development costs can lead to high prices of the drug in the market and other factors are creating obstacles in the Tyrosine Kinase 2 (TYK2) Inhibitors Market growth.

Scope of Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Drug Insight
• Coverage: Global
• Key Tyrosine Kinase 2 (TYK2) Inhibitors Companies: Alumis, Priovant Therapeutics, Takeda, Galapagos, Oncostellae, Neuron23, Sudo Biosciences, Sareum Holdings PLC, Ventyx Biosciences, Nimbus Therapeutics, Bristol-Myers Squibb, Priovant Therapeutics, and others
• Key Tyrosine Kinase 2 (TYK2) Inhibitors Therapies: ESK-001, Brepocitinib, Zasocitinib, GLPG3667, OST-122, NEU-111, TYK2 Inhibitors, SDC-1801, GLPG3667, VTX958, NDI-034858, Sotyktu, Brepocitinib, and others
• Tyrosine Kinase 2 (TYK2) Inhibitors Therapeutic Assessment: Tyrosine Kinase 2 (TYK2) Inhibitors current marketed and Tyrosine Kinase 2 (TYK2) Inhibitors emerging therapies
• Tyrosine Kinase 2 (TYK2) Inhibitors Market Dynamics: Tyrosine Kinase 2 (TYK2) Inhibitors market drivers and Tyrosine Kinase 2 (TYK2) Inhibitors market barriers

Request for Sample PDF Report for Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/tyk2-kinase-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Tyrosine Kinase 2 (TYK2) Inhibitors Report Introduction
2. Tyrosine Kinase 2 (TYK2) Inhibitors Executive Summary
3. Tyrosine Kinase 2 (TYK2) Inhibitors Overview
4. Tyrosine Kinase 2 (TYK2) Inhibitors- Analytical Perspective In-depth Commercial Assessment
5. Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Therapeutics
6. Tyrosine Kinase 2 (TYK2) Inhibitors Late Stage Products (Phase II/III)
7. Tyrosine Kinase 2 (TYK2) Inhibitors Mid Stage Products (Phase II)
8. Tyrosine Kinase 2 (TYK2) Inhibitors Early Stage Products (Phase I)
9. Tyrosine Kinase 2 (TYK2) Inhibitors Preclinical Stage Products
10. Tyrosine Kinase 2 (TYK2) Inhibitors Therapeutics Assessment
11. Tyrosine Kinase 2 (TYK2) Inhibitors Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Tyrosine Kinase 2 (TYK2) Inhibitors Key Companies
14. Tyrosine Kinase 2 (TYK2) Inhibitors Key Products
15. Tyrosine Kinase 2 (TYK2) Inhibitors Unmet Needs
16 . Tyrosine Kinase 2 (TYK2) Inhibitors Market Drivers and Barriers
17. Tyrosine Kinase 2 (TYK2) Inhibitors Future Perspectives and Conclusion
18. Tyrosine Kinase 2 (TYK2) Inhibitors Analyst Views
19. Appendix
20. About DelveInsight

Latest Reports:
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Post Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.